Last reviewed · How we verify
Co-trimoxazole 12
Co-trimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.
Co-trimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication. Used for Bacterial infections including urinary tract infections, respiratory tract infections, and otitis media, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Toxoplasmosis.
At a glance
| Generic name | Co-trimoxazole 12 |
|---|---|
| Sponsor | Khon Kaen University |
| Drug class | Sulfonamide antibiotic combination |
| Target | Dihydropteroate synthase and dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. Together, they block the bacterial synthesis of dihydrofolate and tetrahydrofolate, nucleotides essential for DNA synthesis. This synergistic dual inhibition provides broad-spectrum bactericidal activity against many gram-positive and gram-negative organisms.
Approved indications
- Bacterial infections including urinary tract infections, respiratory tract infections, and otitis media
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Toxoplasmosis
Common side effects
- Rash
- Nausea
- Vomiting
- Diarrhea
- Hyperkalemia
- Stevens-Johnson syndrome
- Hepatotoxicity
Key clinical trials
- Prevent TB: Choice Architecture for TPT Delivery (NA)
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Sulfamethoxazole Prophylaxis Duration After Renal Transplantation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-trimoxazole 12 CI brief — competitive landscape report
- Co-trimoxazole 12 updates RSS · CI watch RSS
- Khon Kaen University portfolio CI